SpyGlass Pharma, Inc.

SGP · NasdaqGS · Stock · Healthcare

$23.69

-0.96% today

Delayed price, 2026-10-15 13:12 UTC

What SpyGlass Pharma does

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

Key facts

Sector

Healthcare

Industry

Biotechnology

Market cap

$792.4M

P/E (ttm)

—

Forward P/E

-8.4

Dividend yield

0.00%

Beta

—

Profit margin

0.0%

Employees

Headquarters

Irvine, CA, United States

Exchange

NasdaqGS

Website

www.spyglasspharma.com

Performance

1 Month

-18.5%

3 Months

+19.8%

6 Months

-5.0%

1 Year

-10.3%

5 Years

-8.6%

$17.0652-week range$32.44

Biggest setback — last 12 months

-37.1%

16 Feb 2026 → 8 Jun 2026

Fell from $29.32 to $18.44 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+57.7%

8 Jun 2026 → 14 Sept 2026

Ran from $18.44 to $29.08 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Mixed

Price is not consistently aligned with its short- and long-term averages.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$20.31 (-14.3%)	$23.69	$27.63 (+16.6%)
3 Months	$18.15 (-23.4%)	$23.69	$30.93 (+30.5%)
6 Months	$16.25 (-31.4%)	$23.69	$34.54 (+45.8%)
12 Months	$13.90 (-41.3%)	$23.69	$40.37 (+70.4%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 53.3%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

SPTX

Seaport Therapeutics, Inc.

$16.68 · +3.7%

ANRO

Alto Neuroscience, Inc.

Collegium Pharmaceutical, Inc.

Lexicon Pharmaceuticals, Inc.

$1.60 · -0.6%

Recent insider activity

Acquired 7,392,301 shares at $16.00 — Behbahani Ali, Director · 2026-02-11

Acquired 7,392,301 shares at $16.00 — Florence Anthony A. Jr., 10% Owner · 2026-02-11

Acquired 7,392,301 shares at $16.00 — BASKETT FOREST, 10% Owner · 2026-02-11

Acquired 6,035,038 shares at $16.00 — New Enterprise Associates 17, L.P., 10% Owner · 2026-02-11

Acquired 6,035,038 shares at $16.00 — Yang Rick, 10% Owner · 2026-02-11

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.